Iroquois Capital Group

RS Metrics is the only provider of asset-level environment, climate, and physical risk metrics for all stakeholders. In 2023, we partnered with Google Cloud to democratize access to our over 100 asset-level metrics via SAAS, DAAS or Dashboards. Our ESGSignals® and AssetTracker products build on 10+ years of a model-driven architecture, coupled with our AI, ML, data science, and financial product expertise that address the need for independent, verifiable, and timely environmental insights. ​RS Metrics + GCP Design Pattern is a ready-made climate risk analytics design pattern for lending and investment portfolios using cloud-native tools and granular geospatial datasets (e.g. calculating physical climate risk for sustainable finance). The Reference Design Pattern shown only covers two out of the numerous metrics (water stress and fire risk) we offer through ESGSignals. ESGSignals® has 100+ ARD (Analysis Ready Data) metrics covering ESG and environmental, climate, and physical risk metrics. The asset-level ARD metrics are real-time, auditable, and scalable making it quick and easy for objective valuation

Covenant Physician Partners is a privately-held owner and operator of ambulatory surgery centers. Its services include using minimally invasive and robotic technology to screen for colorectal cancers, polyp removal, and surgery of the digestive tract as well as various examinations and diagnoses of the rectum area that enable patients to get proper detection of their diseases.

ACS Partners provides construction services in the commercial and residential markets. ACS' services include renovations to multi-family complexes, student housing complexes, and single-family residential complexes.

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.

Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.

Soligenix is a late-stage research and development biopharmaceutical company that focuses on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early-stage development to advanced development and manufacturing.

TapImmune engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., SAFC Pharma, Inc., and National Institute of Allergy and Infectious Diseases. The company was founded in 1999 and is based in Vancouver, Canada.

Sevion is a biopharmaceutical company which discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The Company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. The Company’s antibody pipeline is being developed from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multispanning membrane proteins and ion channels that play an important role in multiple diseases. The Company also developed the first protein nanocage system allowing delivery of nucleic acids and other payloads to target cells.

Biomoda, Inc., a development state company, operates as an invitro diagnostics company that develops assays or tests to detect cancer. The company's non-invasive diagnostic is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. It also involves in developing collection protocol and diagnostics for other cancers, including breast, oral, prostate, bladder, colorectal, and cervical. The company has an agreement with the New Mexico Institute of Mining and Technology through the New Mexico Department of Veterans Services for a clinical study for the early detection of lung cancer of the state's veterans. In addition, it has a collaborative agreement with Medical Acoustics, LLC to purchase its Lung Flute as part of the collection protocol in a clinical study. Further, the company has contracts with Quintiles Consulting and Alquest, Inc. who help to guide Biomoda through the FDA approval process. It has a strategic relationship with Obio. The company was founded in 1990 and is headquartered in Albuquerque, New Mexico.

SinoHub, Inc. engages in electronic component sales, outsourced electronics product production and sales, and electronic component supply chain management (SCM) services in the People’s Republic of China and Hong Kong. Its electronic component sales include procurement-fulfillment and electronic component sales to manufacturers. The company’s SCM services include warehousing, delivery, and import/export. It offers SinoHub SCM, a proprietary, Web-based software system that provides order entry with automated price and category checking, order tracking, inventory management information system, shipment information system, payment system, finished orders database, operations results tracking, executive reporting system, shipment tracking, bonded inventory control system, vendor managed inventory, and VAT tracking for recovery on export. The company provides its products to contract manufacturers and design houses, as well as to OEMs and EMS companies. SinoHub, Inc. is headquartered in Shenzhen, the People’s Republic of China.

VeriTeQ is a technology company focused on animal and emergency identification solutions. Its products are utilized around the world in such applications as pet identification using its patented, FDA-approved implantable microchip; livestock identification and tracking using visual and radio frequency identification (RFID) ear tags; and global positioning systems (GPS) search and rescue beacons for use on aircraft, ships and boats, and by adventure enthusiasts. The company was founded in 1993 and headquartered in Delray Beach, Florida.

CEL-SCI Corporation is a biotechnology company. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.

Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. It was established in 1994 and is headquartered in Lexington, Massachusetts.

ACE*COMM Corporation provided operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Its OSS solutions were applicable to various networks that include wired, wireless, voice, data, multimedia, and Internet communications networks. ACE*COMM marketed and sold its solutions in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. It had strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. The company was founded in 1983 and was headquartered in Gaithersburg, Maryland.

Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Migo Software, Inc. engages in the development, acquisition, and marketing of software and infrastructure technologies designed for the storage and accession of personalized mobile information. Its flagship product, Migo, allows users to synchronize their personalized computing environments, including email, digital media, and other data; and application settings to portable storage devices, such as flash/hard disk drives, smart phones, and MP3 players. The company also offers XP to Vista Easy-Sync Suite that provides a safety net and applications support for users transitioning their data and computing environment to a new or upgraded computer running Microsoft’s Windows Vista Operating System; Registry Repair, which fixes computer problems, such as system lock-ups and freezes; PC BackUp, a disaster recovery tool that simplifies the computer backup process; and Recover Lost Data, an utility for retrieving files. In addition, it provides Digital Vault/Portable Vault, Digital File Shedder, DriveWasher, and Easy PC Transfer that offer a line of backup, system utility, and online security/privacy for the users. Migo Software sells its products primarily through original equipment manufacture partnerships, resellers, and through its Web site in the United States and internationally. The company was formerly known as Powerhouse Technologies Group, Inc. and changed its name to Migo Software, Inc. in 2006. Migo Software is headquartered in Redwood City, California.

Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

BravoSolution US provides on-demand supply management solutions to companies primarily in the United States and Europe. It offers various supply management software & services in areas, such as program management, spend analysis, eSourcing, contract management, and supplier performance management. The company was formerly known as Verticalnet Inc. and changed its name to BravoSolution US in January 2008. The company was incorporated in 1995 and is based in Malvern, Pennsylvania. As of January 25, 2008, BravoSolution US operates as a subsidiary of BravoSolution SpA.

Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company's products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. Pharmacopeia has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Cranbury, New Jersey. As of December 23, 2008, Pharmacopeia, Inc. operates as a subsidiary of Ligand Pharmaceuticals Inc.